Phosphodiesterase-4 inhibition attenuates pulmonary inflammation in neonatal lung injury

European Respiratory Journal

Volumn 31, Issue 3, 2008, Pages 633-644

  De Visser, Y P ^a   Walther, F J ^a,b   Laghmani, E H ^a   Van Wijngaarden, S ^a   Nieuwland, K ^a   Wagenaar, G T M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

Bronchopulmonary dysplasia; Coagulation; Fibrin deposition; Oxidative stress; Piclamilast; Rolipram

Indexed keywords

PHOSPHODIESTERASE IV; PICLAMILAST; ROLIPRAM; 3 (CYCLOPENTYLOXY) N (3,5 DICHLORO 4 PYRIDYL) 4 METHOXYBENZAMIDE; 3-(CYCLOPENTYLOXY)-N-(3,5-DICHLORO-4-PYRIDYL)-4-METHOXYBENZAMIDE; BENZAMIDE DERIVATIVE; PHOSPHODIESTERASE INHIBITOR; PYRIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DRUG INHIBITION; FEMALE; FIBRINOLYSIS; HYPEROXIA; LUNG DYSPLASIA; LUNG INJURY; NONHUMAN; OXIDATIVE STRESS; PNEUMONIA; PRIORITY JOURNAL; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ADULT RESPIRATORY DISTRESS SYNDROME; ANIMAL; ARTIFICIAL VENTILATION; CHEMISTRY; CYTOLOGY; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION PROFILING; HUMAN; INFLAMMATION; LUNG ALVEOLUS; LUNG FIBROSIS; LUNG LAVAGE; NEWBORN; PATHOLOGY; WISTAR RAT;

ANIMALS; ANIMALS, NEWBORN; BENZAMIDES; BRONCHOALVEOLAR LAVAGE FLUID; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; DISEASE MODELS, ANIMAL; GENE EXPRESSION PROFILING; HUMANS; INFANT, NEWBORN; INFLAMMATION; PHOSPHODIESTERASE INHIBITORS; PULMONARY ALVEOLI; PULMONARY FIBROSIS; PYRIDINES; RATS; RATS, WISTAR; RESPIRATION, ARTIFICIAL; RESPIRATORY DISTRESS SYNDROME, ADULT; ROLIPRAM;

EID: 42949130166     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00071307     Document Type: Article

References (54)

1. Jobe AH, Ikegami M. Mechanisms initiating lung injury in the preterm. Early Hum Dev 1998; 53: 81-94.
2. Goodman G, Perkin RM, Anas NG, Sperling DR, Hicks DA, Rowen M. Pulmonary hypertension in infants with bronchopulmonary dysplasia. J Pediatr 1988; 112: 67-72.
3. Aranda JV, Grondin D, Sasyniuk BI. Pharmacologic considerations in the therapy of neonatal apnea. Pediatr Clin North Am 1981; 28: 113-133.
4. Harris MC, Baugart S, Rooklin AR. Successful extubation of infants with respiratory distress syndrome using aminophylline. J Pediatr 1983; 103: 303-305.
5. ter Horst SAJ, Wagenaar GTM, de Boer E, et al. Pentoxifylline reduces fibrin deposition and prolongs survival in neonatal hyperoxic lung injury. J Appl Physiol 2004; 97: 2014-2019.
6. Wagenaar GTM, ter Horst SAJ, van Gastelen MA, et al. Gene expression profile and histopathology of experimental bronchopulmonary dysplasia induced by prolonged oxidative stress. Free Radic Biol Med 2004; 36: 782-801.
7. Johnsson R. Effect of pentoxifylline on red cell flexibility and cation transport in healthy subjects and patients with hereditary spherocytosis. Scan J Haematol 1979; 23: 81-87.
8. Bacher A, Eggensperger E, Koppensteiner R, Mayer N, Klimscha W. Pentoxifylline attenuates the increase in whole blood viscosity after transfusion. Acta Anaesthesiol Scand 2005; 49: 41-46.
9. Sullivan GW, Carper HT, Novick WJ, Mandell GL. Inhibition of the inflammatory action of interleukin-1 and tumor necrosis factor (alpha) on neutrophil function by pentoxifylline. Infect Immun 1988; 56: 1722-1729.
10. Mandell GL. ARDS, neutrophils, and pentoxifylline. Am Rev Repir Dis 1988; 138: 1103-1105.
11. Mandell GL. Cytokines, phagocytes, and pentoxifylline. J Cardiovascular Pharmacol 1995; 25: Suppl. 2, S20-S22.
12. Conti M, Richter W, Mehats C, Livera G, Park J, Jin C. Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic amp signaling. J Biol Chem 2003; 278: 5493-5496.
13. Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol Ther 2006; 109: 366-398.
14. Houslay MD, Schafer P, Zhang KYJ. Phosphodiesterase-4 as a therapeutic target. Drug Discov Today 2005; 10: 1503-1519.
15. Spina D. Phosphodiesterase-4 inhibitors in the treatment of inflammatory lung disease. Drugs 2003; 63: 2575-2594.
16. Griswold DE, Webb EF, Breton J, White JR, Marshall PJ, Torphy TJ. Effect of selective phospodiesterase type IV inhibitor, rolipram, on fluid and cellular phases of inflammatory response. Inflammation 1993; 17: 333-344.
17. Spond J, Chapman R, Fine J, et al. Comparison of PDE 4 inhibitors, rolipram and SB 207499 (Ariflo™), in a rat model of pulmonary neutrophilia. Pulm Pharmacol Ther 2001; 14: 157-164.
18. Underwood DC, Kotzer CJ, Bochnowicz S, et al. Comparison of phosphodiesterase III, IV and dual III/IV inhibitors on bronchospasm and pulmonary eosinophil influx in guinea pigs. J Pharmacol Exp Ther 1993; 270: 250-259.
19. Miotla JM, Teixeira MM, Hellewell PG. Suppression of acute lung injury in mice by an inhibitor of phosphodiesterase type 4. Am J Respir Cell Mol Biol 1997; 18: 411-420.
20. Manning CD, Burman M, Christensen SB, et al. Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B. Br J Pharmacol 1999; 128: 1393-1398.
21. Compton CH, Gubb J, Nieman R, et al. Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose ranging study. Lancet 2001; 358: 265-270.
22. Schmidt BMW, Kusma M, Feuring M, et al. The phosphodiesterase 4 inhibitor roflumilast is effective in the treatment of allergic rhinitis. J Allergy Clin Immunol 2001; 108: 530-536.
23. Timmer W, Leclerc V, Birreaux G, et al. The new phosphodiesterase 4 inhibitor roflumilast is efficacious in exercise-induced asthma and leads to suppression of LPS-stimulated TNF-α ex vivo. J Clin Pharmacol 2002; 42: 297-303.
24. Huang Z, Mancini JA. Phosphodiesterase 4 inhibitors for the treatment of asthma and COPD. Curr Med Chem 2006; 13: 3253-3262.
25. Dijkstra CD, Dopp EA, Joling P, Kraal G. The heterogeneity of mononuclear phagocytes in lymphoid organs: distinct macrophage subpopulations in the rat recognized by monoclonal antibodies ED1, ED2 and ED3. Immunology 1985; 54: 589-599.
26. Hui KY, Haber E, Matsueda GR. Monoclonal antibodies to a synthetic fibrin-like peptide bind to human fibrin but not fibrinogen. Science 1983; 222: 1129-1132.
27. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001; 29: E45.
28. Underwood DC, Osborn RR, Noval LB, et al. Inhibition of antigen-induced bronchoconstriction and eosinophil infiltration in the guinea pig by the cyclic AMP-specific phosphodiesterase inhibitor, rolipram. J Pharmacol Exp Ther 1993; 266: 306-313.
29. Howell RE, Jenkins LP, Howell DE. Inhibition of lipopolysaccharide- induced pulmonary edema by isozyme-selective phosphodiesterase inhibitors in guinea pigs. J Pharmacol Exp Ther 1995; 275: 703-709.
30. Howell RE, Jenkins LP, Fielding LE, Grimes D. Inhibition of antigen-induced pulmonary eosinophilia and neutrophilia by selective inhibitors of phosphodiesterase types 3 or 4 in brown Norway rats. Pulmonary Pharmacol 1995; 8: 83-89.
31. Hill EV, Sheppard CL, Cheung Y, Gall I, Krause E, Houslay MD. Oxidative stress employs phosphatidyl inositol 3-kinase and ERK signalling pathways to activate cAMP phosphodiesterase-4D3 (PDE4D3) through multisite phosphorylation at Ser239 and Ser579. Cell Signal 2006; 18: 2056-2069.
32. Millen J, MacLean MR, Houslay MD. Hypoxia-induced remodelling of PDE4 isoform expression and cAMP handling in human pulmonary artery smooth muscle cells. Eur J Cell Biol 2006; 85: 679-691.
33. Papandreou I, Powell A, Lim AI, Denko N. Cellular reaction to hypoxia: sensing and responding to an adverse environment. Mutat Res 2005; 569: 87-100.
34. Barazzone C, Belin D, Piguet PF, Vassalli JD, Sappino AP. Plasminogen activator inhibitor-1 in acute hyperoxic mouse lung injury. J Clin Invest 1996; 98: 2666-2673.
35. Carraway MS, Welty-Wolf KE, Miller DL, et al. Blockade of tissue factor: treatment for organ injury in established sepsis. Am J Respir Crit Care Med 2003; 167: 1200-1209.
36. Sitrin RG, Pan PM, Srikanth S, Todd III RF. Fibrinogen activates NF-κB transcription factors in mononuclear phagocytes. J Immunol 1998; 161: 1462-1470.
37. Gupta M, Hernandez-Juviel JM, Waring AJ, Bruni R, Walther FJ. Comparison of functional efficacy of surfactant protein B analogues in lavaged rats. Eur Respir J 2000; 16: 1129-1133.
38. Sachs BD, Baillie GS, McCall JR, et al. p75 neurotrophin receptor regulates tissue fibrosis through inhibition of plasminogen activation via a PDE4/cAMP/PKA pathway. J Cell Biol 2007; 177: 1119-1132.
39. Ortiz JL, Cortijo J, Valles JM, Bou J, Morcillo EJ. Rolipram inhibits airway microvascular leakage induced by platelet-activating factor, histamine and bradykinin. J Pharmacol 1993; 45: 1090-1092.
40. Kooistra MRH, Corada M, Dejana E, Bos JL. Epac1 regulates integrity of endothelial cell junction through VE-cadherin. FEBS Lett 2005; 579: 4966-4972.
41. 3H]rolipram binding activity and their relationship to emetic behavior in the ferret. J Med Chem 1996; 39: 120-125.
42. Barnette MS, Grous M, Cieslinski LB, Burman M, Christensen SB, Torphy TJ. Inhibitors of phosphodiesterase IV (PDE IV) increase acid secretion in rabbit isolated gastric glands: correlation between function and interaction with high-affinity rolipram binding site. J Pharmacol Exper Ther 1995; 273: 1396-1402.
43. Gerhardt T, McCarthy J, Bancalari E. Effect of aminophylline on respiratory center activity and metabolic rate in premature infants with idiopathic apnea. Pediatrics 1979; 63: 537-542.
44. Milsap RL, Krauss AN, Auld PAM. Oxygen consumption in apneic premature infants after low-dose theophylline. Clin Pharmacol Ther 1980; 28: 536-540.
45. Bauer J, Maier K, Linderkamp O, Hentschel R. Effect of caffeine on oxygen consumption and metabolic rate in very low birth weight infants with idiopathic apnea. Pediatrics 2001; 107: 660-663.
46. Supinski GS, Deal EC Jr, Kelsen SG. The effects of caffeine and theophylline on diaphragmatic contractility. Am Rev Respir Dis 1984; 130: 429-433.
47. Fredholm BB. Adenosine, adenosine receptors and the action of caffeine. Pharmacol Toxicol 1995; 76: 93-101.
48. Herlenius E, Lagercrantz H, Yamamoto Y. Adenosine modulates inspiratory neurons and the respiratory pattern in the brainstem of neonatal rats. Pediatr Res 1997; 42: 46-53.
49. von Poblotzki M, Rieger-Fackeldey E, Schulze A. Effects of theophylline on the pattern of spontaneous breathing in preterm infants less than 1000 g of birth weight. Early Hum Dev 2003; 72: 47-55.
50. Schmidt B, Roberts RS, Davis P, et al. Long-term effects of caffeine therapy for apnea of prematurity. N Engl J Med 2007; 357: 1893-1902.
51. Juliana AE, Abbad FCB. Severe persistent pulmonary hypertension of the newborn in a setting where limited resources exclude the use of inhaled nitric oxide: successful treatment with sildenafil. Eur J Pediatr 2005; 164: 626-629.
52. Baquero H, Soliz A, Neira F, Venegas ME, Sola A. Oral sildenafil in infants with persistant pulmonary hypertension of the newborn: a pilot randomized blinded study. Pediatrics 2006; 117: 1077-1083.
53. Ladha F, Bonnet S, Eaton F, Hashimoto K, Korbutt G, Thebaud B. Sildenafil improves alveolar growth and pulmonary hypertension in hyperoxia-induced lung injury. Am J Respir Crit Care Med 2005; 172: 750-756.
54. Lipworth BJ. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet 2005; 365: 167-175.